SANSHO is a bio venture company and was established on January 2008. We are developing a new treating drug of osteoarthritis(OA) which is low molecule compound. W got IND from US FDA and Taiwanese FDA and now conducting clinical trial phase 1/b including patients of OA. Phase 1/b trial consist of 32 OA patients and four groups for dose escalating method. The lowest dose is 50ug/body for injection in the knee and the first group (8 patients)are completed and now is stepping next dose (200ug/body). The trial will be completed at the middle of this year and going next step after phase 1/b.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
2-carba cyclic phosphatidic acid
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):